PMV Pharmaceuticals, Inc. (PMVP) Key Metrics
PMVP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $91.4M
- Enterprise value
- −$5.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.0 10-yr median 1.1
- EV / EBITDA
- 1.2
- Dividend yield
- —
- Beta
- 1.35
PMVP key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPMVP valuation Price multiples at each fiscal year-end price.
PMVP returns How much profit the business earns on the capital it uses.
PMVP per-share figures Results divided by the shares outstanding at year-end.
PMVP financial health Debt, liquidity and how easily interest is covered.
PMVP efficiency & capital use Working capital cycle and where the cash goes.
PMVP valuation history
PMVP returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PMVP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PMVP price vs earnings per share
PMVP key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $65.7M | $77.9M | $148.8M | $396.7M | $1.04B | $2.75B | — | — |
| Enterprise value | −$46.4M | −$90.4M | −$40.9M | $169.6M | $756.7M | $2.39B | — | — |
| Price / book | 0.6 | 0.4 | 0.7 | 1.6 | 3.4 | 7.7 | — | — |
| Earnings yield | −118.4% | −75.4% | −46.3% | −18.5% | −5.5% | −1.3% | — | — |
| Free cash flow yield | −112.1% | −66.7% | −38.0% | −18.1% | −4.6% | −1.2% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $1.25 | $1.51 | $3.10 | $8.70 | $23.10 | $61.51 | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Earnings per share | −$1.48 | −$1.14 | −$1.44 | −$1.61 | −$1.28 | −$0.77 | −$0.59 | — |
| Operating cash flow per share | −$1.40 | −$0.99 | −$1.16 | −$1.40 | −$1.03 | −$0.73 | −$0.51 | — |
| Free cash flow per share | −$1.40 | −$1.01 | −$1.18 | −$1.57 | −$1.06 | −$0.73 | −$0.52 | — |
| Cash per share | $2.15 | $3.29 | $4.23 | $5.29 | $6.58 | $8.07 | $2.36 | — |
| Book value per share | $1.99 | $3.41 | $4.70 | $5.40 | $6.84 | $8.02 | −$1.64 | — |
| Tangible book value per share | $1.99 | $3.41 | $4.70 | $5.40 | $6.84 | $8.02 | −$1.64 | — |
| Capex per share | $0.00 | $0.01 | $0.02 | $0.18 | $0.03 | $0.00 | $0.00 | — |
| Debt per share | $0.02 | $0.02 | $0.28 | $0.31 | $0.25 | — | $3.93 | — |
| Shares outstanding | 52.5M | 51.6M | 48.0M | 45.6M | 45.1M | 44.8M | 43.0M | — |
| Change in shares outstanding | +1.9% | +7.4% | +5.3% | +1.0% | +0.8% | +4.1% | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −55.4% | −29.2% | −29.2% | −26.4% | −17.3% | −23.9% | — | — |
| Return on invested capital (ROIC) | — | −308.7% | −230.8% | −293.0% | −454.0% | — | — | — |
| Return on assets (ROA) | −50.5% | −26.5% | −26.4% | −24.4% | −16.6% | −14.7% | −30.5% | −27.6% |
| Return on tangible assets | −66.7% | −30.7% | −27.3% | −27.1% | −17.4% | −9.4% | −24.6% | −27.6% |
| Financial health | ||||||||
| Total debt | $838,000 | $1.2M | $13.3M | $14.0M | $11.2M | — | $168.9M | $107.2M |
| Cash & short-term investments | $112.9M | $169.5M | $203.1M | $241.1M | $297.2M | $361.4M | $101.5M | $61.9M |
| Net debt | −$112.1M | −$168.3M | −$189.8M | −$227.1M | −$286.0M | −$361.4M | $67.4M | $45.3M |
| Debt / equity | 0.01 | 0.01 | 0.06 | 0.06 | 0.04 | — | — | — |
| Debt / assets | 0.01 | 0.01 | 0.05 | 0.05 | 0.03 | — | 1.64 | 1.69 |
| Current ratio | 10.09 | 12.22 | 14.78 | 22.80 | 24.66 | 56.90 | 22.57 | 26.75 |
| Quick ratio | 10.09 | 12.22 | 14.78 | 22.80 | 24.66 | 56.90 | 22.57 | 26.75 |
| Interest coverage | — | — | — | -19.1 | -75.0 | -42.3 | -20.6 | — |
| Working capital | $103.8M | $161.3M | $193.4M | $236.2M | $289.1M | $358.4M | $97.6M | $59.9M |
| Invested capital | −$7.4M | $7.8M | $35.9M | $18.9M | $22.6M | −$2.3M | −$3.0M | −$819,000 |
| Tangible asset value | $104.7M | $176.1M | $225.7M | $246.0M | $308.6M | $359.1M | −$70.5M | −$46.1M |
| Net current asset value | $103.4M | $160.4M | $180.9M | $222.7M | $278.3M | $358.4M | −$71.4M | −$47.4M |
| Graham net-net per share | $1.92 | $2.99 | $3.68 | $4.75 | $6.07 | $7.93 | −$1.67 | — |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | — | — |
| Capex / depreciation | 0.22 | 0.57 | 0.77 | 25.35 | 4.39 | 0.47 | 0.28 | 1.34 |
| Efficiency | ||||||||
| Days payables outstanding | 13,356.8 | 1,565.9 | 905.0 | 1,736.6 | 683.3 | 2,550.4 | 1,822.6 | 1,120.9 |
| Payables turnover | 0.03 | 0.23 | 0.40 | 0.21 | 0.53 | 0.14 | 0.20 | 0.33 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $4.9M | $4.9M | $3.1M | $3.1M | $2.4M | $2.2M | $1.9M | $1.0M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from PMVP's annual financial statements (latest annual report filed March 6, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PMVP valuation and financial ratios
PMV Pharmaceuticals earned a return on equity of −55.4% in fiscal 2025. It ended the year with $0.8 million of debt and $112.9 million in cash and short-term investments, a net cash position of $112.1 million.
See the PMVP income statement, the PMVP chart for price history, or the PMVP stock overview for the latest quote and news.
PMVP key metrics FAQ
What is PMV Pharmaceuticals's return on equity?
PMV Pharmaceuticals's return on equity (ROE) was −55.4% in fiscal 2025: net income of -$77.7 million on average shareholders' equity of $140.4 million.
How much debt does PMV Pharmaceuticals have?
PMV Pharmaceuticals had total debt of $0.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is PMV Pharmaceuticals's free cash flow yield?
PMV Pharmaceuticals generated -$73.6 million of free cash flow in fiscal 2025, a free cash flow yield of −112.1% on its market value at year-end ($65.7 million).
What is PMV Pharmaceuticals's current ratio?
PMV Pharmaceuticals's current ratio was 10.09 at the end of fiscal 2025: current assets were 10.09 times current liabilities.